Barracuda Invest AS has, following NorDiag’s agreement to buy minimum 90.1 per cent of outstanding shares in Genpoint AS dated March 1 2007, committed itself to buy 46 060 shares in NorDiag ASA at a share price of NOK 8,50. Barracuda’s holding of NorDiag shares will, following this transaction, be 65 060 shares. The subscription of the shares will be executed after the extraordinary meeting in NorDiag ASA which will be held at March 16 2007. Barracuda Invest AS is a company owned by Mårten Wigstøl, who is chairman of the board and the new CEO in NorDiag ASA.

Novel Diagnostics ASA has, following the same agreement, committed itself to buy 588 235 shares in a private placement following the previous mentioned agreement, which the board of directors of NorDiag ASA has proposed for the extraordinary general meeting at March 16 2007. Novel Diagnostics will following this subscription own 3 845 660 shares in NorDiag. Hans Hekland is chairman of the board of directors in Novel Diagnostics and member of the board of directors in NorDiag ASA.